Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC) utilizes big data IT
Date : 11/1/2015
We’ve gone from treating every child exactly the same way to being able to develop individualized therapies. We’re now able to stop the progression of cancer in 60 percent of our patients, and today some are cancer-free.
Dr. Giselle Sholler, Chair of the NMTRC and Director of the Pediatric Oncology Research Program at Helen DeVos Children’s Hospital, United States
ChallengePhysicians wanted to improve outcomes for patients battling diseases including neuroblastoma and medulloblastoma, but this required the development of new treatments.
SolutionA team of oncologists, pediatricians, geneticists and patient families established the Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC) to treat patients using precision medicine.
Benefits• Achieves remission in patients previously deemed incurable
• Improves long-term health outcomes for cancer survivors
• Increases scientific understanding of cancer and genes
• Gathers big data that can facilitate medical breakthroughs
• Shows organizations how to implement precision medicine